血管生成
癌症研究
PI3K/AKT/mTOR通路
基质凝胶
蛋白激酶B
生物
细胞生长
肝细胞癌
内皮干细胞
信号转导
细胞生物学
生物化学
体外
作者
Defa Huang,Wenjuan Zhang,Jie Chen,Zhigang Jiao,Xiaoling Wang,Dingyu Rao,Weisong Li,Die Hu,Fangfang Xie,Xiaoxing Wang,Zheng-Zhe Li,Xiaomei Yi,Ji-Yang Wu,Yu Jiang,Qi Wang,Tianyu Zhong
出处
期刊:Extracellular vesicles and circulating nucleic acids
[OAE Publishing Inc.]
日期:2023-10-12
卷期号:4 (4): 532-47
被引量:3
标识
DOI:10.20517/evcna.2023.30
摘要
Aim: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. The process of HCC development is closely related to angiogenesis. Plasma exosomes have diagnostic value in many diseases and have become a current research hotspot. We aimed to identify a key molecule in small extracellular vesicles (sEVs) involved in angiogenesis as a diagnostic marker for HCC and uncover the mechanism underlying its regulation in the angiogenesis process. Methods: Nano‐flow cytometer (nFCM) was used to detect CD147 expression in plasma-derived sEVs in 155 HCC patients, 59 liver cirrhosis (LC), and 82 healthy donors (HD). The mechanism of hepatocellular carcinoma cell-derived sEVs CD147 promoting angiogenesis was elucidated by cell proliferation assay, scratch wound healing assay, transwell assay, tube formation assay, and in vivo Matrigel plug angiogenesis assay. Results: We found that CD147 expression was significantly higher in HCC tissue samples than in normal tissues. We also found a significantly larger number of CD147-positive small extracellular vesicles (CD147+ sEVs) in the plasma of HCC patients than LC patients and HD. Furthermore, we showed that hepatocellular carcinoma cell (HepG2)-derived CD147+ sEVs promoted cell proliferation, migration, invasion, and angiogenesis in human umbilical vein endothelial cells. The CD147+ sEVs upregulated vascular endothelial growth factor A (VEGFA) by activating the PI3K/Akt pathway, thereby promoting angiogenesis. Conclusion: HCC-derived sEVs-associated CD147 serves as a diagnostic marker and promotes endothelial cell angiogenesis via the PI3K/Akt pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI